Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.83 USD | +1.80% | -3.74% | +111.19% |
03-20 | Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024 | |
03-20 | Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 196M 268M |
---|---|---|---|---|---|
Net income 2024 * | -41M -56.05M | Net income 2025 * | -53M -72.45M | EV / Sales 2024 * | - |
Net cash position 2024 * | 116M 159M | Net cash position 2025 * | 199M 272M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.08
x | P/E ratio 2025 * |
-6.28
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.72% |
Latest transcript on Trevi Therapeutics, Inc.
1 day | +0.90% | ||
1 week | -3.74% | ||
Current month | -17.97% | ||
1 month | -15.77% | ||
3 months | +77.99% | ||
6 months | +54.64% | ||
Current year | +111.19% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Thomas Sciascia
FOU | Founder | 70 | 10-12-31 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 21-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 18-10-09 |
James Cassella
BRD | Director/Board Member | 69 | 20-02-12 |
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.83% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 2.83 | +1.80% | 5 825 |
24-04-26 | 2.78 | +9.45% | 56,183 |
24-04-25 | 2.54 | -4.15% | 179,237 |
24-04-24 | 2.65 | -7.02% | 124,912 |
24-04-23 | 2.85 | -3.06% | 172,800 |
Delayed Quote Nasdaq, April 29, 2024 at 10:42 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+111.19% | 196M | |
-2.51% | 103B | |
+1.67% | 95.28B | |
+1.43% | 22.15B | |
-15.53% | 21.02B | |
-8.45% | 18.15B | |
-41.01% | 16.73B | |
-13.62% | 16.05B | |
+4.00% | 13.68B | |
+34.54% | 12.17B |
- Stock Market
- Equities
- TRVI Stock